
UK pharmacy chain Boots today announced the launch of SureLeaf, a specialist medical cannabis service giving eligible patients living with chronic pain, generalized anxiety disorder or insomnia access to consultant-led assessment, treatment and ongoing clinical care.
It's a significant step forward for the legal cannabis market in the country.
The new service expands the range of specialist healthcare available through Boots Online Doctor, giving eligible patients another treatment option to consider and greater access to clinical expertise.
“At Boots, we’re committed to making healthcare more accessible and helping people find the right support for their individual needs. Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy. Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care. Ultimately, it’s about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life," said Jamie Kerruish, chief healthcare officer at Boots, in a statement.
SureLeaf brings together specialist consultants, multidisciplinary clinical oversight and ongoing patient monitoring throughout treatment. Patients aged 25 or over with an eligible condition can begin their assessment online, with suitability reviewed by the clinical team before progressing to a video consultation with a consultant in the relevant medical specialty who is on the General Medical Council Specialist Register.
Any proposed prescription will be independently reviewed by a multidisciplinary clinical team that includes a second, independent consultant, before treatment begins. Patients must have previously tried conventional treatments without achieving adequate symptom relief.
Once treatment begins, patients will receive ongoing clinical support and monitoring, including an initial review after 28 days followed by reviews at least every three months. Validated questionnaires will be used throughout treatment to assess relevant areas including quality of life, pain, anxiety, sleep and mood, helping clinicians monitor the effectiveness of treatment.
“Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis. SureLeaf has therefore been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate. Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins," said Dr. David Gwynne, medical director for Boots Online Doctor, in a statement.
Alongside the launch, Boots and the University of Nottingham are exploring a collaborative research programme to build on the existing real-world evidence and understanding of medical cannabis in chronic pain management.
The work would build on the existing partnership between the two organisations, which is based on a shared commitment to improve patient care through evidence led innovation and aims to help inform future clinical practice, support responsible service development and contribute to the broader understanding of the role medical cannabis could play.






















